[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100636110":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":12,"locations":18,"responsibleParty":36,"collaborators":10,"id":40,"slug":41,"hasResults":42,"nctId":43,"briefTitle":44,"officialTitle":44,"acronym":45,"eligibilityCriteria":46,"healthyVolunteers":42,"sex":47,"minAge":48,"maxAge":10,"enrollmentInfo":49,"targetDuration":10,"studyType":52,"phases":10,"briefSummary":53,"conditions":54,"keywords":57,"overallStatus":21,"whyStopped":10,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":69},{"fullName":5,"class":6},"Arbor Research Collaborative for Health","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"External control: DOPPS cohort",null,"DOPPS study in Europe",[13],{"name":14,"role":15,"phone":16,"phoneExt":10,"email":17},"Roberto Pecoits-filho, MD","CONTACT","7342108046","Roberto.Pecoits@arborresearch.org",[19],{"facility":20,"status":21,"city":22,"state":10,"zip":10,"country":23,"countryCode":24,"cosmosGeoPoint":25,"geoPoint":30,"contacts":31},"AURA","RECRUITING","Paris","France","FR",{"type":26,"coordinates":27},"Point",[28,29],2.3488,48.85341,{"lat":29,"lon":28},[32,35],{"name":33,"role":15,"phone":16,"phoneExt":10,"email":34},"Pablo Urena, MD","urena.pablo@wanadoo.fr",{"name":14,"role":15,"phone":16,"phoneExt":10,"email":17},{"type":37,"investigatorFullName":38,"investigatorTitle":39,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Roberto Pecoits-Filho","Research Scientist","100636110","comparisons-of-biochemical-and-clinical-outcomes-of-hemodialysis-patients-treated-with-middle-cut-off-dialyzers-versus-high-flux-hemodialysis-or-hemodiafiltration-100636110",false,"NCT07561424","Comparisons Of Biochemical And Clinical Outcomes Of Hemodialysis Patients Treated With Middle Cut-Off Dialyzers Versus High-Flux Hemodialysis Or Hemodiafiltration","CONCORDIA","Inclusion Criteria\n\n* 18 years of age or older\n* Treated at an in-centre dialysis clinic\n* Receiving chronic, maintenance HD","ALL","18 Years",{"count":50,"type":51},1000,"ESTIMATED","OBSERVATIONAL","The CONCORDIA study is a retrospective, observational study evaluating clinical and biochemical outcomes among patients receiving maintenance hemodialysis with medium cut-off (MCO) dialyzers (Theranova) compared with high-flux hemodialysis (HF-HD) and hemodiafiltration (HDF). Using real-world data from non-DOPPS Theranova sites and the DOPPS cohort as an external control, the study aims to assess whether MCO dialyzers are associated with improved outcomes versus HF-HD and non-inferior outcomes compared with HDF. The primary outcome is all-cause mortality, with secondary outcomes including cardiovascular events, hospitalizations, infections, and laboratory measures related to anemia, mineral metabolism, and inflammation.",[55,56],"ESKD","Dialysis Patients",[58,59],"dialysis","HDF","2026-04-28",{"date":62,"type":63},"2026-05-01","ACTUAL",{"date":65,"type":63},"2026-02-01",{"date":67,"type":51},"2026-09-01",{"name":5,"class":6},1]